BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 20118828)

  • 1. Targeting liposomes toward novel pediatric anticancer therapeutics.
    Federman N; Denny CT
    Pediatr Res; 2010 May; 67(5):514-9. PubMed ID: 20118828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic therapeutic delivery using navigable agents.
    Martel S
    Ther Deliv; 2014 Feb; 5(2):189-204. PubMed ID: 24483196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligand-based targeted therapy for cancer tissue.
    Das M; Mohanty C; Sahoo SK
    Expert Opin Drug Deliv; 2009 Mar; 6(3):285-304. PubMed ID: 19327045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biophotonic techniques for manipulation and characterization of drug delivery nanosystems in cancer therapy.
    Spyratou E; Makropoulou M; Mourelatou EA; Demetzos C
    Cancer Lett; 2012 Dec; 327(1-2):111-22. PubMed ID: 22265863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer drug delivery with nanoparticles.
    Conti M; Tazzari V; Baccini C; Pertici G; Serino LP; De Giorgi U
    In Vivo; 2006; 20(6A):697-701. PubMed ID: 17203748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.
    Danhier F; Feron O; Préat V
    J Control Release; 2010 Dec; 148(2):135-46. PubMed ID: 20797419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surface-active liposomes for targeted cancer therapy.
    Sofou S
    Nanomedicine (Lond); 2007 Oct; 2(5):711-24. PubMed ID: 17976032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EPR-effect: utilizing size-dependent nanoparticle delivery to solid tumors.
    Stylianopoulos T
    Ther Deliv; 2013 Apr; 4(4):421-3. PubMed ID: 23557281
    [No Abstract]   [Full Text] [Related]  

  • 11. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise.
    Bharali DJ; Mousa SA
    Pharmacol Ther; 2010 Nov; 128(2):324-35. PubMed ID: 20705093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine.
    Al-Jamal WT; Kostarelos K
    Acc Chem Res; 2011 Oct; 44(10):1094-104. PubMed ID: 21812415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanotechnology platforms and physiological challenges for cancer therapeutics.
    Kim KY
    Nanomedicine; 2007 Jun; 3(2):103-10. PubMed ID: 17442621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity.
    Pulkkinen M; Pikkarainen J; Wirth T; Tarvainen T; Haapa-aho V; Korhonen H; Seppälä J; Järvinen K
    Eur J Pharm Biopharm; 2008 Sep; 70(1):66-74. PubMed ID: 18555675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticle technologies for cancer therapy.
    Alexis F; Pridgen EM; Langer R; Farokhzad OC
    Handb Exp Pharmacol; 2010; (197):55-86. PubMed ID: 20217526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
    Taurin S; Nehoff H; Greish K
    J Control Release; 2012 Dec; 164(3):265-75. PubMed ID: 22800576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle therapeutics: an emerging treatment modality for cancer.
    Davis ME; Chen ZG; Shin DM
    Nat Rev Drug Discov; 2008 Sep; 7(9):771-82. PubMed ID: 18758474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells.
    Mai J; Song S; Rui M; Liu D; Ding Q; Peng J; Xu Y
    J Control Release; 2009 Nov; 139(3):174-81. PubMed ID: 19576253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer.
    Malam Y; Loizidou M; Seifalian AM
    Trends Pharmacol Sci; 2009 Nov; 30(11):592-9. PubMed ID: 19837467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of nanoparticles in cancer: drug delivery and diagnostics.
    Talekar M; Kendall J; Denny W; Garg S
    Anticancer Drugs; 2011 Nov; 22(10):949-62. PubMed ID: 21970851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.